Business Description
Abera Bioscience AB
ISIN : SE0015245097
Share Class Description:
XSAT:ABERA: Ordinary SharesCompare
Compare
Traded in other countries / regions
ABERA.Sweden8WK.Germany IPO Date
2021-02-24Description
Abera Bioscience AB is a platform and vaccine development company based on research in the medical, molecular, and microbiological fields. The company's mission is to develop vaccine candidates based on its novel vaccine delivery platform to late pre-clinical or early clinical phase.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.78 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -91.6 | |||||
| 3-Year EPS without NRI Growth Rate | -91.6 | |||||
| 3-Year FCF Growth Rate | -80.7 | |||||
| 3-Year Book Growth Rate | 49.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.18 | |||||
| 9-Day RSI | 44.35 | |||||
| 14-Day RSI | 43.6 | |||||
| 6-1 Month Momentum % | 11.56 | |||||
| 12-1 Month Momentum % | -3.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.26 | |||||
| Quick Ratio | 1.26 | |||||
| Cash Ratio | 0.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.3 | |||||
| Shareholder Yield % | -10.77 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -161.66 | |||||
| ROA % | -130.6 | |||||
| ROIC % | -471.12 | |||||
| ROCE % | -161.65 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 7.71 | |||||
| Price-to-Tangible-Book | 10.6 | |||||
| EV-to-EBIT | -3.41 | |||||
| EV-to-EBITDA | -3.41 | |||||
| EV-to-FCF | -3.59 | |||||
| Price-to-Net-Current-Asset-Value | 114 | |||||
| Earnings Yield (Greenblatt) % | -29.35 | |||||
| FCF Yield % | -26.71 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Abera Bioscience AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -35.14 | ||
| Beta | 0 | ||
| Volatility % | 65.54 | ||
| 14-Day RSI | 43.6 | ||
| 14-Day ATR (kr) | 0.346766 | ||
| 20-Day SMA (kr) | 4.7635 | ||
| 12-1 Month Momentum % | -3.09 | ||
| 52-Week Range (kr) | 3.05 - 7.5 | ||
| Shares Outstanding (Mil) | 14.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Abera Bioscience AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Abera Bioscience AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Abera Bioscience AB Frequently Asked Questions
What is Abera Bioscience AB(XSAT:ABERA)'s stock price today?
The current price of XSAT:ABERA is kr4.56. The 52 week high of XSAT:ABERA is kr7.50 and 52 week low is kr3.05.
When is next earnings date of Abera Bioscience AB(XSAT:ABERA)?
The next earnings date of Abera Bioscience AB(XSAT:ABERA) is 2024-05-14.
Does Abera Bioscience AB(XSAT:ABERA) pay dividends? If so, how much?
Abera Bioscience AB(XSAT:ABERA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers